Related Experiment Video
Updated: Jan 1, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
Published on: May 3, 2018
The double dealing of cyclin D1
Guergana Tchakarska1, Brigitte Sola2
1Department of Human Genetics, McGill University Health Centre, McGill University, Montreal, Montreal, Quebec, Canada.
Abstract:
The cell cycle is tightly regulated by cyclins and their catalytic moieties, the cyclin-dependent kinases (CDKs). Cyclin D1, in association with CDK4/6, acts as a mitogenic sensor and integrates extracellular mitogenic signals and cell cycle progression. When deregulated (overexpressed, accumulated, inappropriately located), cyclin D1 becomes an oncogene and is recognized as a driver of solid tumors and hemopathies. Recent studies on the oncogenic roles of cyclin D1 reported non-canonical functions dependent on the partners of cyclin D1 and its location within tumor cells or tissues. Support for these new functions was provided by various mouse models of oncogenesis. Finally, proteomic and transcriptomic data identified complex cyclin D1 networks. This review focuses on these aspects of cyclin D1 pathophysiology, which may be crucial for targeted therapy.Abbreviations: aa, amino acid; AR, androgen receptor; ATM, ataxia telangectasia mutant; ATR, ATM and Rad3-related; CDK, cyclin-dependent kinase; ChREBP, carbohydrate response element binding protein; CIP, CDK-interacting protein; CHK1/2, checkpoint kinase 1/2; CKI, CDK inhibitor; DDR, DNA damage response; DMP1, cyclin D-binding myb-like protein; DSB, double-strand DNA break; DNA-PK, DNA-dependent protein kinase; ER, estrogen receptor; FASN, fatty acid synthase; GSK3β, glycogen synthase-3β; HAT, histone acetyltransferase; HDAC, histone deacetylase; HK2, hexokinase 2; HNF4α, and hepatocyte nuclear factor 4α; HR, homologous recombination; IR, ionizing radiation; KIP, kinase inhibitory protein; MCL, mantle cell lymphoma; NHEJ, non-homologous end-joining; PCAF, p300/CREB binding-associated protein; PGC1α, PPARγ co-activator 1α; PEST, proline-glutamic acid-serine-threonine, PK, pyruvate kinase; PPAR, peroxisome proliferator-activated receptor; RB1, retinoblastoma protein; ROS, reactive oxygen species; SRC, steroid receptor coactivator; STAT, signal transducer and activator of transcription; TGFβ, transforming growth factor β; UPS, ubiquitin-proteasome system; USP22, ubiquitin-specific peptidase 22; XPO1 (or CRM1) exportin 1.
Insights
Cyclin D1, a key cell cycle regulator, acts as an oncogene when deregulated, driving tumors. Recent research reveals its non-canonical functions and complex networks, offering new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- The cell cycle is regulated by cyclin-dependent kinases (CDKs) and cyclins.
- Cyclin D1, partnered with CDK4/6, senses mitogenic signals and controls cell cycle progression.
- Deregulation of cyclin D1 (overexpression, accumulation, abnormal localization) transforms it into an oncogene, driving various cancers.
Purpose of the Study:
- To review recent findings on the oncogenic roles of cyclin D1.
- To explore non-canonical functions of cyclin D1 influenced by its binding partners and cellular location.
- To highlight the potential of these insights for developing targeted therapies.
Main Methods:
- Review of recent scientific literature on cyclin D1.
- Analysis of data from mouse models of oncogenesis.
- Examination of proteomic and transcriptomic data identifying cyclin D1 networks.
Main Results:
- Cyclin D1 exhibits non-canonical functions beyond cell cycle regulation.
- These functions depend on cyclin D1's interaction partners and subcellular localization.
- Mouse models support these novel oncogenic roles.
- Proteomic and transcriptomic analyses reveal complex cyclin D1-associated networks.
Conclusions:
- Cyclin D1's pathophysiology involves non-canonical functions crucial for cancer development.
- Understanding these complex networks and interactions is vital for advancing targeted cancer therapies.
Related Concept Videos
Positive Regulator Molecules
Positive Regulator Molecules
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Anaphase Promoting Complex
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...

